A new study may kickstart new prostate cancer therapies, especially for more aggressive forms of the disease.
Prostate cancer is a leading cause of death in men worldwide. When patients stop responding to traditional therapies, they often fight an uphill battle against an aggressive form of the disease.
Findings from a new study may change that trajectory.
Researchers in Korea have identified zinc finger protein 507 (ZNF507) as the key contributor to the progression of prostate cancer in its most aggressive form. In studying human tissues, they found significantly elevated levels of ZNF507 in the diseased samples versus the normal tissues.
Published in the Journal of Experimental & Clinical Cancer Research, the study also suggests that ZNF507 accelerates the growth of advanced stage prostate cancer.
The researchers hope that these findings will lead to future prostate cancer therapies. There are already advances being made in prostate cancer screenings — a crucial step for early detection of the disease.
HALO Diagnostics offers each of these screenings at the Prostate Laser Center in Houston, TX, and our site in Indian Wells, CA. If you or a loved one are looking to schedule a prostate cancer diagnostic test, give us a call:
Houston center: (713) 904-4014
Indian Wells center: (760) 322-8883
To schedule a complimentary case assessment, fill out the form below.
You should always consult with your doctor(s) when considering treatment options. HALO Dx provides MRI-guided prostate screenings, MRI-guided prostate biopsy, liquid “biopsy” tests, and genomic testing to facilitate informed decisions between doctors and patients. Learn more about HALO Dx's advanced, minimally invasive prostate cancer and BPH treatments including Laser Focal Therapy and TULSA-PRO for whole gland and partial ablations. With the appropriate diagnostic results, our prostate disease experts help you answer any questions you may have about prostate cancer or BPH.